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associated with metastasis and poor prognosis in
gastric carcinoma
Xiaofang Xing1†, Shenyi Lian2†, Ying Hu3†, Ziyu Li4, Lianhai Zhang4, Xianzi Wen1, Hong Du3, Yongning Jia4,
Zhixue Zheng4, Lin Meng2, Chengchao Shou2* and Jiafu Ji1*Abstract
Background: PRL-3 is a member of phosphatases of regenerating liver family, characterized by phosphatase active
domain and C-terminal prenylation motif. Overexpression of PRL-3 has been implicated in multiple cancers. Here
we examined the clinical significance of PRL-3 in gastric cancer together with its metastatic biological functions
utilizing different structural mutants.
Methods: PRL-3 expression was analyzed immunohistochemically in 196 gastric cancer patients and 21 cases of
liver metastasis. A series of wild type PRL-3 or its mutant plasmids were expressed in BGC823 cells to investigate
the relationship between its catalytic activity, cellular localization and metastatic potential in vitro.
Results: Positive staining of PRL-3 was observed in 19.4% (38/196) gastric cancer tissues compared with 76.2%
(16/21) in liver metastasis. Statistical analysis revealed that PRL-3 expression correlated with lymph node metastasis and
vascular invasion (P < 0.05). Patients with high PRL-3 expression showed poorer 5-year overall survival (P = 0.011). Wild
type PRL-3 expressing cells resulted in enhanced migration and invasion ability, which were greatly crippled in form of
PRL-3(C104S) or PRL-3(ΔCAAX) mutants accompanied with its alteration in subcellular localization.
Conclusions: Metastasis associated protein PRL-3 may serve as a potential prognostic biomarker in human gastric
cancer. Both the phosphatase catalytic activity and cellular localization are critical for its function.
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Despite a decrease in incidence in recent decades, gas-
tric cancer is still the second leading cause of cancer-
related death worldwide, especially for those in advanced
stages with metastatic lesions that still has a rather poor
outcome [1]. As clinicians move towards personalized
cancer medicine, there is an urgent need to understand
and identify key factors involved in the biology of metas-
tasis, not only to predict gastric cancer outcome, but* Correspondence: scc@bjcancer.org; jiafuj@hotmail.com
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stated.also to select a subset of population for appropriate tar-
geted therapy before disease progression.
PRL-3 (phosphatase of regenerating liver-3, also known
as PTP4A3) belongs to the the family of protein tyrosine
phosphatases (PTPs). PTPs are important for regulating
phosphorylation of many crucial signalling molecules and
take effect on cell cycle, proliferation, differentiation and
transformation [2]. Using serial analysis of gene expression
(SAGE), PRL-3 was first identified as the only gene that is
consistently overexpressed in all 18 liver metastases de-
rived from colorectal cancer, but at low levels in primary
tumors and normal epithelium [3]. Since then, PRL-3
overexpression has been reported to be related with the
poor prognosis of multiple cancers, including colorectal
cancer [4-6], breast cancer [7], lung cancer [8], ovarian
cancer [9], and hepatocellular cancer [10]. Mostly, it has
been found to be associated with metastasis and has beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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gressiveness. In gastric cancer, Miskad et al. observed high
expression in primary tumors and higher expression in
lymph node metastasis (68.1% and 92.6%, respectively) [11].
Similar results were obtained by Li et al. [12]. However,
these research were conducted utilizing polyclonal anti-
bodies, which might have cross-reaction with other PRL
family members (PRL-1 and PRL-2) considering their
high homology [2]. Afterwards, Wang et al. found that
overexpression of PRL-3 was present in 47.7% of gastric
carcinomas with the lymph node metastasis using mono-
clonal antibody [13] and reported its prognostic significance
[13]. Although correlation between PRL-3 overexpression
and lymph node metastasis or peritoneal metastasis has
been reported at some aspects in gastric cancer [12,14],
the identical expression in the primary tumors without
metastasis, primary tumors with metastasis, and matched
samples of primary lesion and liver metastasis has not
been completely understood. Also, the prognostic value of
PRL-3 expression has not been reached a consensus on its
clinical significance.
PRL-3 is composed of 173 amino acids and is a monomer
with a complex structure [15]. Enzyme active site is located
at position 103–110, where Cys104 is the enzymatic
nucleophile [16]. Our previous studies have found that
PRL-3 interacted with integrin α1, downregulated tyrosine
phosphorylation of integrin β1, enhanced the phosphor-
ylation of ERK1/2 and further increased the gelatinolytic
activity of gelatinase MMP-2, thus finally promoted metas-
tasis in colon cancer cells [4,17]. Some other studies also re-
ported its prometastatic function through reconstruction
of the cell cytoskeleton [18], epithelial-mesenchymal
transition [19,20] and angiogenesis process [21,22]. As
PRL-3 is a phosphatase, it is important to investigate
whether its catalytic activity itself is directly involved
in the cancer metastasis.
Moreover, PRL-3 contains C-terminal CAAX sequence
for prenylation, which is a common post-translational
modification for proteins that are targeted to membranes
and enables participation in their signalling pathways [23].
Zeng et al. reported that PRL-3 was mainly located at
plasma membrane and the early endosomes with a small
fraction of unprenylated proteins in the nucleus [24]. Given
that CAAX motif is not only responsible for prenylation
which enables correct cellular localization, but also plays an
additional role in the regulation of PRL-3 by inhibiting its
catalytic activity. Here we explored the role of prenylation
of the CAAX motif in PRL-3′s cellular localization and in
the process of gastric cancer cell metastasis.
In the present study, we first detected PRL-3 expression
in primary gastric carcinoma with or without metastasis
and in 21 cases of matched liver metastases using immu-
nohistochemistry. The aim was to evaluate the association
between PRL-3 overexpression and clinical pathologicalfactors and analyze its impact on survival. Then, prometa-
static effects of wild type PRL-3 and its catalytic inactive
and CAAX motif deleted mutants were observed in vitro
in order to clarify the importance of its catalytic activity
and subcellular localization for its functional role in the
regulation of metastasis.
Materials and methods
Patients and tissue specimens
A total of 196 gastric cancer patients who underwent
surgical resection from February 1998 to January 2007 at
Peking University Cancer Hospital were analyzed. The
records of patients were reviewed in the context of clini-
copathological and follow-up information. The stage of
gastric cancer was classified according to the American
Joint Committee on Cancer stage (AJCC 7th edition). The
OS (Overall Survival) was calculated starting from the date
of the initial surgery to the time of death, counting death
from any cause as the end point or the last date of follow-
up as the end point, if no event was documented. All pa-
tients were followed up until November 2011. None of the
patients received preoperative chemotherapy or radiation
therapy. After gastrectomy, resected specimens were proc-
essed routinely for macroscopic pathological assessment.
Informed consent was obtained from each patient.
Immunohistochemistry analysis
The validation of the PRL-3 antibody 3B6 used for im-
munohistochemistry has been described previously [25].
Four-μm sections from formalin-fixed, paraffin-embedded
tissues were mounted on poly-L-lysine-coated slides and
then deparaffinized in xylene and rehydrated through
graded alcohol to distilled water. Endogenous peroxidase
activity was then blocked by incubation in 3% hydrogen
peroxide–methanol for 10 min. After washing with phos-
phate–buffered saline, the slides were blocked with 5%
skim milk for 60 min and then incubated with PRL-3
monoclonal antibody 3B6 [25] (5 μg ⁄ ml) overnight at 4°C.
EnVision + TM (Dako, Carpinteria, CA, USA) was used as
the secondary antibody. Antibody binding was visualized
by a standard streptavidin immunoperoxidase reaction,
followed by chromogen detection with diaminobenzidine
for 10 min and haematoxylin counterstaining. Immuno-
reactivity in the cytoplasma and cytoplasmic membrane
was evaluated.
Semiquantitative immunohistochemical scoring
Evaluation of PRL-3 immunoreactivity was carried out
independently by three experienced pathologists without
any knowledge of the clinical data. All tissue samples were
assessed in a consecutive analysis to ensure maximal in-
ternal consistency. The analysis was assessed according
to both the percentage of positive cells and the intensity
of cytoplasmic reactivity. Each histological section was
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imum tumour positivity. At 200 or 400 magnification,
cells were analyzed from five areas of maximum tumour
positivity in each case and the average percentage of
positive cells was recorded. As described in our previous
study [6], these averaged values were stratified into five
scoring groups:-, not detected; ±, <10% positive cells; +,
10–20% weakly to moderately positive cells; ++, 10–20%
intensely positive cells or 20–50% weakly positive cells;
and +++, 20–50% positive cells with moderate to marked
reactivity or >50% positive cells. There was a high level of
consistency among the three pathologists, and in the few
discrepant cases (<5%) a consensus was reached after joint
review. On statistical analysis, and ± were considered
negative, + and above were considered positive.
Reagents and cell culture
Monoclonal antibody 3B6 against PRL-3 was generated as
previously described [25]. Gastric cancer cell line BGC823
(ATCC, Manassas, VA) were maintained in RPMI-1640
medium (Invitrogen) supplemented with 10% fetal calf
serum.
Plasmids and transfection
Myc-tagged wild type PRL-3 cDNA [GenBank: NM_032611]
was inserted into pcDNA3.1 at BamH I/Xba I sites to gen-
erate a mammalian expression plasmid pcDNA3.1-PRL-3
as previously described [4]. Then, the catalytically inactive
mutant of PRL-3(C104S) was created by standard PCR
based site-directed mutagenesis using the Easy Mutagenesis
System (Transgene Biotech). (forward primer: CAG GCC
CGC CAC AGA GTG CAC AGC; reverse primer: GCT
GTG CAC TCT GTG GCG GGC CTG with the substituted
nucleotides encoding serine at the site of 104 instead of
cysteine. PcDNA3.1-PRL-3(ΔCAAX) was constructed by
insertion of PRL-3 sequence with C-terminal CAAX motif
truncated into pcDNA3.1 plasmid (forward primer: CGC
GGA TCC ATG GCC CGC ATG AAC CGG, reverse pri-
mer: CCG GAATTC TCA CCG GGT CTT GTG CGT
GTG TGG GTC). They were transfected into BGC823 cells
with Lipofectamine 2000 (Invitrogen) to generate wild type
PRL-3, PRL-3(C104S), and PRL-3(ΔCAAX) stably express-
ing and control cell pools, respectively. After 4 weeks of
selection with 600 μg/mL of Geneticin (Invitrogen), PRL-3
expression was verified by RT-PCR and Western blot.
Plasmid pEGFP-C1-PRL-3, pEGFP-C1-PRL-3(C104S) and
pEGFP-C1-PRL-3(ΔCAAX) was generated by ligating
BamH I/EcoR I digested full-length PRL-3, mutant PRL-
3(C104S) and mutant PRL-3(ΔCAAX) to Bgl II/EcoR I
digested pEGFP-C1 vector (Clontech, Palo Alto, CA).
Immunofluorescence
To visualize green fluorescent protein (GFP) tagged
PRL-3, BGC823 cells were transfected with pEGFP-C1,pEGFP-C1-PRL-3, pEGFP-C1-PRL-3(C104S) or pEGFP-
C1-PRL-3(ΔCAAX). For immunofluorescence assays,
BGC823 cells were transiently transfected and fixed with
4% paraformaldehyde for 10 min at room temperature,
followed with DAPI(sigma) staining of 10 min. Cover slips
were mounted on glass slides with 50% glycerol/phosphate-
buffered saline and imaged using a Leica SP2 confocal
system (Leica Microsystems, Dresden, Germany).
Western blot
Cells were homogenized in lysis buffer (50 mM Tris–HCl,
pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM DTT, 1 mM phe-
nylmethylsulfonyl fluoride, 10 mM NaF, 1 mM Na3VO4,
1 × protease cocktail) for 20 min at 4°C. The supernatant
was collected after centrifugation at 12,000 × g for 20 min
at 4°C and subjected to Western blot with GAPDH for the
internal reference. PRL-3 antibody 3B6 was verified pre-
viously [25]. Documentation of blots was performed by
scanning with an EPSON PERFECTION 2580 scanner and
acquired images were adjusted by the Auto-Contrast com-
mand of Photoshop CS (Adobe, San Jose, CA).
Motility and invasion assays
For transwell chamber-based motility and invasion as-
says, equal amounts of cells were loaded into an insert
provided with serum-free medium and allowed to pass
through an 8-μm-pore polycarbonate filter, which had
been either pre-coated with 100 μg of Matrigel (Becton
Dickinson, San Jose, CA) for invasion assay or left un-
coated for motility assay. Medium supplemented with
10% fetal calf serum was added to the bottom chamber.
Cells on the upper surface of filters were wiped out after
24 h (motility assay) or 48 h (invasion assay), and those
on the undersurface were stained with 1% amino toluene
blue and counted under a microscope.
Statistical analysis
A standard chi-squared test was performed to assess the
association between PRL-3 expression and the clinicopatho-
logical parameters. Survival curves were estimated by the
Kaplan–Meier method and compared with the log rank test.
Multivariate analysis was performed using the Cox regres-
sion model (a backward selection) to assess whether a factor
was an independent predictor of disease free survival (DFS).
Hazard ratios (HRs) with 95% confidence intervals (CIs)
were estimated. A two tailed P-value of <0.05 was considered
statistically significant. All statistical analyses were performed
with SPSS v18.0 software (SPSS Inc., Chicago, IL, USA).
Results
Association of PRL-3 expression and
clinicopathological factors
PRL-3 expression in 196 primary gastric tumor speci-
mens and 21 cases of liver metastasis was determined
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protein mainly localized at cytomembrane and endomem-
brane systems, sometimes presented as granulated loci in
the cytoplasm in the intensely positive samples (Figure 1).
According to the criteria, positive expression(>10%) was
found in 38 out of 196 neoplasms and 16 out of 21 liver
metastasis (19.4% versus 76.2%, P < 0.001). In the 21 paired
samples of primary cancer and liver metastasis, consistency
of PRL-3 expression is observed with positive rate of 57.1%
(12/21) and 76.2% (16/21), respectively (P < 0.05). Among
them, we found one patient with positive PRL-3 expression
developed liver metastasis 2 years after surgery, at that time
no clinical detectable metastasis existed initially (Figure 1).
Statistical analysis further showed positive associations of
PRL-3 expression with lymph node involvement and vascu-
lar invasion (P = 0.000). Patients with lymph node status at
N2 and N3 showed higher expression rates than those with
lymph node status at N0 and N1 stage (27.8% (N2 +N3)
versus 11.1% (N0 +N1), P = 0.006). Patients with positive
vascular invasion also showed increased expression com-
pared with those without (32.9% versus 11.4%, P = 0.000,
Table 1). Likewise, we also observed a trend showing more
elevated expression in the gastric cancer in advanced stages
than in early stages [24.8% (stage III and IV) versus 12.0%
(stage I and II)], or with distant metastasis than without
distant metastasis (33.3% versus 17.7%), although there is
no statistical significance (Table 1).Figure 1 Immunohistochemical staining of PRL-3 expression in gastri
carcinoma (x200); C. PRL-3 moderate expression in gastric carcinoma (x200
cytomembrane with some granulated loci in cytoplasm (x400, magnificatio
(x200); F. PRL-3 expression in matched liver metastasis developed 2 years aPRL-3 expression predicted worse overcome in gastric cancer
As expected, clinical TNM stage, depth of tumor invasion,
lymph node status, metastasis, vascular invasion and tumor
location were significantly associated with clinical outcome
(P < 0.01, Table 2). Patients with high level of PRL-3 ex-
pression exhibited significant poorer 5-year overall survival
(OS) compared with patients with low level of PRL-3
(31.8% versus 51.7%, P = 0.011, Table 2, Figure 2A). A
multivariate Cox proportional hazards model using vari-
ables associated with survival in our study (depth of wall
invasion, lymph node metastasis, vascular invasion, distant
metastasis, tumor location and PRL-3 expression) revealed
that although the impact of PRL-3 on survival was less
evident than vascular invasion (HR: 7.973, P = 0.011), tumor
invasion (HR: 2.578, P = 0.020), and lymph node metastasis
(HR: 5.520, P = 0.004), the risk of patients with positive
PRL-3 expression dying from the disease was still 2.088
times higher than those with negative PRL-3 expression
(P = 0.027). Thus, PRL-3 expression was an independent
risk factor in gastric cancer outcome (Table 3).
To further analyze the prognosis potential of PRL-3
in gastric cancer, patients were divided into subgroups
according to differentiation. In the subgroup of well
and moderately differentiated patients, PRL-3 expres-
sion was significantly associated with overall survival
(59.2% versus 17.7%, P = 0.001, Figure 2B). Also, in the
subgroup of unmetastatic gastric cancer, patients withc cancer. A. Negative control; B. PRL-3 mild expression in gastric
); D. Cellular location of PRL-3 expression, mainly localized in the
n of D.); E. Intense expression of PRL-3 in the primary gastric carcinoma
fter surgery (x200, E and F are from the same patient).
Table 1 Association of PRL-3 expression with
clinicopathological parameters in gastric cancer
Variables Patients
(n)






<60 93 77 (82.8) 16 (17.2) 0.540 0.463
≥60 103 81 (78.6) 22 (21.4)
Sex
Male 146 123 (84.2) 23 (15.8) 4.837 0.128
Female 50 35 (70.0) 15 (30.0)
Diagnosis*
GC 177 145 (81.9) 32 (18.1) 2.001 0.217
GEC 19 13 (68.4) 6 (31.6)
TNM stage
I 33 29 (87.9) 4 (12.1) 6.170 0.100
II 50 44 (88.0) 6 (12.0)
III 92 71 (77.2) 21 (22.8)
IV 21 14 (66.7) 7 (33.3)
Tumor invasion
T1 20 17 (85.0) 3 (15.0) 1.654 0.659
T2 27 23 (85.2) 4 (14.8)
T3 78 64 (82.1) 14 (17.9)
T4 71 54 (76.1) 17 (23.9)
Lymph node metastasis
Negative 59 52 (88.1) 7 (11.9) 12.298 0.006
N1 40 36 (90.0) 4 (10.0)
N2 34 28 (82.4) 6 (17.6)
N3 63 42 (66.7) 21 (33.3)
Metastasis
Negative 175 144 (82.3) 31 (17.7) 2.927 0.138
Positive 21 14 (66.7) 7 (33.3)
Differentiation
Well 13 12 (92.3) 1 (7.7) 1.781 0.410
Moderately 89 69 (77.5) 20 (22.5)
Poor 94 77 (81.9) 17 (18.1)
Histology
Adenocarcinoma 154 126 (81.8) 28 (18.2) 0.669 0.413
Others 42 32 (76.2) 10 (23.8)
Vascular invasion
Negative 123 109 (88.6) 14 (11.4) 13.543 0.000
Positive 73 49 (67.1) 24 (32.9)
*GC: Gastric cancer; GEC: Gastroesophageal Cancer. Statistical analysis showed
significant positive associations of PRL-3 expression with lymph node involve-
ment and vascular invasion.
Table 2 Univariate analysis of survival in gastric cancer






<60 93 65.3% ± 0.056 0.716
≥60 103 63.1% ± 0.052
Sex
Male 146 81.5% ± 0.034 0.764
Female 50 50.3% ± 0.082
Diagnosis*
GC 177 83.1% ± 0.029 0.006
GEC 19 10.6% ± 0.092
TNM stage
I 33 74.3% ± 0.078 0.000
II 50 53.1% ± 0.239
III 92 52.1% ± 0.060
IV 21 15.6% ± 0.082
Tumor invasion
T1 20 50.0% ± 0.354 0.000
T2 27 53.1% ± 0.225
T3 78 53.8% ± 0.068
T4 71 35.3% ± 0.071
Lymph node metastasis
Negative 59 55.4% ± 0.145 0.000
N1 40 69.1% ± 0.091
N2 34 18.2% ± 0.064
N3 63 24.2% ± 0.075
Metastasis
Negative 175 86.1% ± 0.027 0.000
Positive 21 15.6% ± 0.082
Differentiation
Well 13 75.2% ± 0.126 0.278
Moderately 89 38.1% ± 0.075
Poor 94 55.2% ± 0.065
Histology
Adenocarcinoma 154 43.7% ± 0.057 0.191
Others 42 65.0% ± 0.091
Vascular invasion
Negative 123 58.3% ± 0.068 0.000
Positive 73 37.0% ± 0.063
PRL-3
Negative 114 51.7% ± 0.061 0.011
Positive 82 31.8% ± 0.090
*GC: Gastric cancer; GEC: Gastroesophageal Cancer. As expected, clinical TNM
stage, depth of tumor invasion, lymph node status, metastasis, vascular invasion
and tumor location were significantly associated with clinical outcome.
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Figure 2 Kaplan–Meier estimates of overall survival (OS) with
respect to PRL-3 expression. A. OS curves stratified by PRL-3
expression in gastric cancer tissues. B. OS curves stratified by PRL-3
expression in the subgroup of well and moderately differentiated
carcinoma. C. OS curves for the subgroups of patients without
distant metastasis stratified by PRL-3 expression.
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with those did not express PRL-3(36.1% versus 55.2%,
P = 0.015, Figure 2C), while there is no significant dif-
ference in the metastatic subpopulation.
Construction of wild type PRL-3 and mutant PRL-3 protein
expression vectors and establishment of stable cell pools
with BGC823
To investigate the biological functions of PRL-3, we
constructed wild-type (WT) and mutant PRL-3 fusion
expression vectors. The mutant Myc-PRL-3(C104S) vector
was consisted of an inactivating mutation of the essential
catalytic cysteine to serine at position 104 in PRL-3 tyrosine
phosphatase (PTP) signature motif (VHCX-AGXXR), which
could abolish its PTP activity. The mutant Myc-PRL-3
(ΔCAAX) are constructed without the CAAX prenyla-
tion motif in the C-terminal, recognization of which
help the correct localization to specific sites within the
cells and further enables participation in their relevant
signal pathway.
The stable BGC823 cell pools expressing Myc-PRL-3-
WT, mutant Myc-PRL-3(C104S) and Myc-PRL-3(ΔCAAX)
were then obtained with transfection and Geneticin selec-
tion. RT-PCR and WB verified their expression (Figure 3).
Together, The wild type EGFP-PRL-3, its mutant EGFP-
PRL-3(C104S) and EGFP-PRL-3(ΔCAAX) vectors were cre-
ated as described and transiently transfected into BGC823
cells. The subcellular localization of PRL-3 and its mutants
were observed by immunofluorescene (Figure 4). The wild
type EGFP-PRL-3 existed in the plasma membranes and
some intracellular structures in the cytoplasm. The catalytic
inactive mutation in EGFP-PRL-3(C104S) did not appear toTable 3 Multivariate analysis of survival in gastric cancer
according to clinicopathologic factors and PRL-3
overexpression
Overall survival
Variables HR 95% CI P
Lower Upper
PRL-3 2.088 2.010 2.759 .027
Tumor invasion 2.578 1.159 5.732 .020
Lymph node metastasis 5.520 1.714 17.774 .004
Tumor size 1.023 1.001 1.455 .083
Vascular invasion 7.973 1.608 39.539 .011
Multivariate analysis showed PRL-3 expression was an independent risk factor
in gastric cancer outcome.
Figure 3 Level of Myc-PRL-3-WT, Myc-PRL-3(C104S), Myc-PRL-3
(ΔCAAX) expression in stable BGC823 cell pools. They are
detected by RT-PCR (A) and Western blot (B). Results shown are
representative of three independent experiments.
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ation. In contrast, the mutant EGFP-PRL-3(ΔCAAX) was
mostly found within the cytoplasm and nuclear.
Metastatic ability of BGC823 cells expressing wild type
Myc-PRL-3 or mutants
The prometastatic capabilities of PRL-3 were analyzed by
transwell chamber in BGC823 cells stably expressing
Myc-PRL-3 fusion proteins or its mutants. Myc-PRL-3-WT
expressing BGC823 cells resulted in a 3.8- and 2.0-fold,
respectively, enhanced migration and invasion to the under
surface compared to control that transfected with mock
(Figure 5). However, Cells expressing Myc-PRL-3(C104S)
had such effects reduced significantly by 48% and 32%
compared with wild type PRL-3 on cellular migration or
invasion, respectively (Figure 5). Likewise, we observed the
increased motility and invasion abilities were also greatly
crippled by 64% and 39% once CAAX motif deleted,
suggesting the important impact of subcellular location
for the biological function of PRL-3.Figure 4 Immunofluorescence of wild type PRL-3 and its mutants. Int
pEGFP-C1-PRL-3-WT, pEGFP-C1-PRL-3(C104S) and pEGFP-C1-PRL-3(ΔCAAX)
lindole (blue). PRL-3 expression was presented as green fluorescence.Discussion
PTPs play a fundamental role in regulating protein phos-
phorylation balance and PRL-3 represent as a member
of a new class of PRL superfamily [2]. In recent years,
PRL-3 expression has been evaluated in various human
cancers and found to be associated with invasion, me-
tastasis, and poor prognosis [5,15,26]. In this report, we
found significant positive association of PRL-3 expres-
sion with lymph node metastasis and vascular invasion.
Patients with distant metastasis or in the advanced stage
also exhibited higher PRL-3 expression, suggesting it as
a biomarker for tumor metastasis and aggressiveness. In
previous studies, Miskad et al. were the first to describe the
role of PRL-3 protein in gastric cancer [11]. Using poly-
clonal antibody, they showed that PRL-3 is positively
correlated with lymph node metastasis and tumor stage.
In the study carried out by Wang et al., PRL-3 expression
was more frequently detected in the lymph node metastasis
than in the matched primary tumor [13]. Our results are
consistent with these literatures, but with a relatively lower
positive rate (19.4%) considering that monoclonal antibody
was utilized in this study to exclude the possibility for
crossacting with the other PRL families. Furthermore,
PRL-3 expression in 21 cases of liver metastasis was re-
ported here for the first time, the positive rate is 76.2%
compared with 57.1% in the matched primary lesions.
Thus, high level of PRL-3 overexpression is observed in
primary gastric tumors, higher in primary tumors with
metastases, and the highest in liver metastatic tumors.
This indicates the specific involvement of PRL-3 protein
in the metastatic process. As expected, survival analysis
showed that patients with PRL-3 positive expression has
a significant worse overall survival compared with those
do not express. Importantly, in the subgroup analysis,
we observed that PRL-3 expression significantly distin-
guished patients’ survival in the population without me-
tastasis, also in the patients with well to moderately
differentiated gastric cancer. This facts may suggest that
PRL-3 could serve as a prognostic factor for predicting
poorer outcome, but not in the late stage when numerous
deregulations have accumulated to the extent that a single
molecule is not enough to explain the overall state ofracellular localization of PRL-3. BGC823 cells were transfected with
expression vectors. Nuclei were stained with 4, 6-diamidino-2-phemy-
Figure 5 Effects of PRL-3-WT/mutations on migration and invasion. A. Migration assay in BGC823 cells expressing Myc-PRL-3-WT, mutant
Myc-PRL-3(C104S) and Myc-PRL-3(ΔCAAX) using transwell chamber; B. Invasion assay in BGC823 cells expressing Myc-PRL-3-WT, mutant Myc-PRL-3
(C104S) and Myc-PRL-3(ΔCAAX). Quantitative analysis of the number of the cells migrated to the lower side of the membrane in migration assay
(C) and invasion assay (D) is shown. All Data are mean ± SE of three independent experiments. *, P < 0.05; **, P < 0.01.
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we propose that PRL-3 is a key metastasis-initiating
gene deregulated early in the metastatic process, driving
metastasis progression from primary to distant sites via
lymphatic or blood circulation. The different positive rates
were reported probably due to the distinguished clones of
antibody used, distinct evaluation criteria or the different
population of patients involved.
As a phosphatase, PRL-3 has a conserved core PTP
domain with the signature C(X)5R active site motif.
Meanwhile, PRL family is known to bear the membrane-
targeting CAAX prenylation motif at COOH-terminus
[28]. In order to explore the relationship between the
catalytic activity and subcellular localization of PRL-3 with
its prometastatic function, we constructed PRL-3 wild
type, its catalytic inactive mutant (C104S) and CAAX
motif deleted mutant (ΔCAAX) vector and investigatedtheir effects on cell migration and invasion in vitro.
Compared to the control group, BGC823 cells transfected
with PRL-3-WT exhibited significant elevated ability of
migration and invasion. However, both the mutants have
greatly abolished this phenomenon, especially for the
mutant PRL-3(ΔCAAX) had its ability decreased to a
more significant degree. The defeat of PRL-3(C104S)
mutant could be explained by its loss of phosphatase
activity or a potential to form an inter- molecular disulfide
bond to act on its downstream targets, which is also
observed in colon cancer in Guo’s study [29]. It is therefore
hypothesized that both the phosphatase catalytic activity
and its cytomembrane location is indispensable for its
function in gastric cancer metastasis. The process may
involve interaction in the signalling pathway on the inner
side of the membrane. Actually, by using a yeast two-
hybrid system, our previous study has identified integrin
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and reduced the phosphorylation level of integrin β1,
hence activating the MAPK pathway and promoting colon
cancer metastasis in vitro and in vivo [4].
Although many proteins with the CAAX family depend
on such modifications for correct location, they can be
targeted to different subcellular sites [30]. In our present
study by immunofluorescent microscopy, GFP-PRL-3-WT
and GFP-PRL-3(C104S) fusion proteins were localized to
cytomembrane and some intracellular structures in the
cytoplasm, while the GFP-PRL-3(ΔCAAX) mutation
resulted in the diversion of the majority of the protein
to the cytoplasma and nuclear. In the detection of gastric
cancer tissue samples with immunohistochemistry, we also
observed its location mainly at cytomembrane and
endomembrane system. Previous study has reported
that PRL-3 are normally associated with the cytoplasmic
face of the plasma membrane and other plasma membrane
processes such as endosome [31]. Though the exact sub-
cellular localization of PRL-3 was not investigated in this
work, our current data suggested, at least that PRL-3 could
locate on the plasma membrane in gastric cancer cells
and further, CAAX motif was the key component for its
localization while cysteine at 104 was not influence its
distribution. These results are consistent with some
previous studies, which found that overexpression of
HA-PRL-3 in colon cancer cells was presented as cell
plasmic membrane localization [5,32], or in the membrane
ruffles, protrusions and some vacuolar-like membrane ex-
tensions [24,33]. But nuclear localization of PRL-3 has also
been reported. These controversial results may be partially
explained by the hypothesis that PRL-3 could shuttle be-
tween the nucleus and cytoplasm. The reasons partly come
from PRL-1, another member of the PRL superfamily. PRL-
1 was reported acting in a prenylation-dependent manner
in the interphase while regulating its spindle dynamics in a
prenylation-independent manner in the mitotic phase, and
finally take functions in cell survival and motility [34,35]. In
present study, we found that deletion of the C-terminus
prenylation motif of PRL-3 promotes their cytoplasma and
nuclear accumulation. There is possibility that reversible
prenylation could regulate PRL-3 nucleo-cytoplasmic distri-
bution and exert different functions, which further re-
searches are still needed. In fact, many proteins containing
the CAAX family are also oncogenes, such as Ras and Rho
superfamily [36,37]. For this reason, investigations into the
mechanisms of farnesylation and prenylation transferase in-
hibitors are becoming a potential new generation of agents
for anticancer treatment [38,39].
Conclusions
In summary, despite substantial advances in cancer therapy,
metastatic disease remains the primary cause of death in
gastric cancer. PRL-3 is one of the numerous genes thathave been directly linked to the process. Our study here in-
dicated that the metastasis associated protein PRL-3 could
be a independent prognostic factor for predicting worse
outcome in gastric cancer. Both its catalytic activity and
CAAX motif for its intracellular localization are critical for
its prometastatic capability, which shedding new light for
further investigation on its downstream pathway. PRL-3 is
becoming increasingly attractive for personalized cancer
therapy for metastatic intervention.
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